[ad_1]
Spirit said its second-quarter revenue will reach about $1.28 billion, lower than previously expected mostly due to lower-than-expected non-ticket revenue, or revenue from items excluded from base ticket prices such as baggage fees, food, and others.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...